Tesamorelin makes the location of fat matter.
“Belly fat” is a roomy phrase, while visceral fat means fat deep in your abdomen, around organs. Tesamorelin’s evidence needs that location kept in view. It prompts the pituitary gland to release growth hormone. EGRIFTA (tesamorelin) is FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, a change in fat distribution; its label says it isn’t for weight-loss management.
The approved use concerns a particular fat location and a particular medical condition, not general weight loss.
Less fat where, and in whom?
A small trial in adults with HIV found greater reductions in visceral and liver fat with tesamorelin than with a dummy treatment. Liver-fat reduction was an experimental finding, not an FDA-approved use. A result in the liver needs that qualification even when the same study also measures abdominal fat.
In longer follow-up research, visceral fat returned after treatment stopped. That makes this a different proposition from a lasting change after a short course.
If your reason for reading is a smaller waist, those details matter. The people studied and the place measured are part of the finding, not fine print.
The hormone effect brings risks too
Tesamorelin raises IGF-1, a growth factor. Its label warns about high IGF-1, raised blood sugar and fluid retention. Swelling, joint pain and injection-site reactions can occur, and the long-term effects of sustained high IGF-1 are unknown.
The label rules out use during pregnancy, with active cancer, with damage to or removal of the pituitary gland, or with an allergy to its ingredients. Past treated cancer calls for careful weighing by the prescriber. The cancer warning isn’t proof that tesamorelin causes cancer.
“The body’s own hormone” can sound reassuring. It doesn’t erase the risks of changing that hormone’s activity.
What the prescription route means
Some doctors prescribe compounded tesamorelin, and some pharmacies make it for individual prescriptions. That preparation is separate from the FDA-approved EGRIFTA product. The trials above don’t establish the safety or effects of a particular compounded preparation.
Promise Peptides (mypromise.com) is one route to prescription care for compounded tesamorelin, for patients in the United States only. A U.S.-licensed clinician reads your history and decides whether to prescribe; some people may not qualify. Compounded medicines aren’t FDA-approved.
I’d keep three questions handy: which preparation is being discussed, how the evidence fits your condition, and how benefit and harm would be checked. A prescription is a decision about care. It can’t promise your result.